vs
Burford Capital Ltd(BUR)与STANDARD BIOTOOLS INC.(LAB)财务数据对比。点击上方公司名可切换其他公司
Burford Capital Ltd的季度营收约是STANDARD BIOTOOLS INC.的1.7倍($33.4M vs $19.6M),Burford Capital Ltd净利率更高(-112.2% vs -177.4%,领先65.2%),STANDARD BIOTOOLS INC.自由现金流更多($-23.1M vs $-29.3M)
伯福德资本成立于2009年,是一家面向法律市场的专业金融服务提供商,总部位于根西岛,业务覆盖全球。该公司为企业法务部门、律师事务所的诉讼、仲裁、资产追回等相关法律活动提供资金支持,同时也提供配套的法律金融咨询服务。
Standard BioTools(原Fluidigm公司)是一家美国生命科学工具企业,主营流式细胞术与组织成像分析用质谱流式系统,以及配套的检测试剂盒与试剂,同时供应自动化基因组分析仪器、各类微流控芯片(又称集成流体电路)及配套试剂耗材,全系列产品及应用场景均可提供定制检测方案与相关服务。
BUR vs LAB — 直观对比
营收规模更大
BUR
是对方的1.7倍
$19.6M
净利率更高
BUR
高出65.2%
-177.4%
自由现金流更多
LAB
多$6.2M
$-29.3M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $33.4M | $19.6M |
| 净利润 | $-37.5M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | -37.9% | -168.5% |
| 净利率 | -112.2% | -177.4% |
| 营收同比 | — | -11.5% |
| 净利润同比 | — | -28.8% |
| 每股收益(稀释后) | $-0.16 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
BUR
LAB
| Q4 25 | $33.4M | — | ||
| Q3 25 | $69.8M | $19.6M | ||
| Q2 25 | $191.3M | $21.8M | ||
| Q1 25 | $118.9M | $40.8M | ||
| Q3 24 | $159.7M | $22.1M | ||
| Q2 24 | $44.3M | $22.5M | ||
| Q1 24 | — | $45.5M | ||
| Q4 23 | — | $28.2M |
净利润
BUR
LAB
| Q4 25 | $-37.5M | — | ||
| Q3 25 | $-19.2M | $-34.7M | ||
| Q2 25 | $88.3M | $-33.5M | ||
| Q1 25 | $30.9M | $-26.0M | ||
| Q3 24 | $53.7M | $-26.9M | ||
| Q2 24 | $-29.9M | $-45.7M | ||
| Q1 24 | — | $-32.2M | ||
| Q4 23 | — | $-19.8M |
毛利率
BUR
LAB
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% | ||
| Q1 24 | — | 53.1% | ||
| Q4 23 | — | 47.6% |
营业利润率
BUR
LAB
| Q4 25 | -37.9% | — | ||
| Q3 25 | 35.5% | -168.5% | ||
| Q2 25 | 74.3% | -118.1% | ||
| Q1 25 | 65.4% | -80.8% | ||
| Q3 24 | 76.1% | -120.9% | ||
| Q2 24 | 32.0% | -134.5% | ||
| Q1 24 | — | -132.2% | ||
| Q4 23 | — | -75.9% |
净利率
BUR
LAB
| Q4 25 | -112.2% | — | ||
| Q3 25 | -27.4% | -177.4% | ||
| Q2 25 | 46.2% | -153.7% | ||
| Q1 25 | 26.0% | -63.8% | ||
| Q3 24 | 33.7% | -122.0% | ||
| Q2 24 | -67.6% | -203.3% | ||
| Q1 24 | — | -70.6% | ||
| Q4 23 | — | -70.2% |
每股收益(稀释后)
BUR
LAB
| Q4 25 | $-0.16 | — | ||
| Q3 25 | $-0.09 | $-0.09 | ||
| Q2 25 | $0.39 | $-0.09 | ||
| Q1 25 | $0.14 | $-0.07 | ||
| Q3 24 | $0.24 | $-0.07 | ||
| Q2 24 | $-0.14 | $-0.12 | ||
| Q1 24 | — | $-0.27 | ||
| Q4 23 | — | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $943.5M | $129.4M |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $2.4B | $399.7M |
| 总资产 | $6.6B | $539.6M |
| 负债/权益比越低杠杆越低 | 0.87× | — |
8季度趋势,按日历期对齐
现金及短期投资
BUR
LAB
| Q4 25 | $943.5M | — | ||
| Q3 25 | $677.7M | $129.4M | ||
| Q2 25 | $372.2M | $158.6M | ||
| Q1 25 | $486.6M | $150.9M | ||
| Q3 24 | — | $210.6M | ||
| Q2 24 | — | $269.8M | ||
| Q1 24 | — | $287.1M | ||
| Q4 23 | — | $51.7M |
总债务
BUR
LAB
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $1.8B | — | ||
| Q1 25 | $1.8B | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M | ||
| Q4 23 | — | $63.5M |
股东权益
BUR
LAB
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.5B | $399.7M | ||
| Q2 25 | $2.5B | $424.5M | ||
| Q1 25 | $2.4B | $454.6M | ||
| Q3 24 | $3.2B | $489.3M | ||
| Q2 24 | $3.1B | $510.3M | ||
| Q1 24 | — | $577.3M | ||
| Q4 23 | — | $-148.1M |
总资产
BUR
LAB
| Q4 25 | $6.6B | — | ||
| Q3 25 | $6.7B | $539.6M | ||
| Q2 25 | $6.3B | $557.0M | ||
| Q1 25 | $6.2B | $579.6M | ||
| Q3 24 | — | $681.5M | ||
| Q2 24 | — | $708.7M | ||
| Q1 24 | — | $777.7M | ||
| Q4 23 | — | $323.1M |
负债/权益比
BUR
LAB
| Q4 25 | 0.87× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.72× | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-29.0M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-29.3M | $-23.1M |
| 自由现金流率自由现金流/营收 | -87.7% | -118.1% |
| 资本支出强度资本支出/营收 | 0.8% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $21.4M | $-111.1M |
8季度趋势,按日历期对齐
经营现金流
BUR
LAB
| Q4 25 | $-29.0M | — | ||
| Q3 25 | $-20.1M | $-22.2M | ||
| Q2 25 | $-84.2M | $-20.7M | ||
| Q1 25 | $155.2M | $-30.3M | ||
| Q3 24 | $-97.4M | $-27.9M | ||
| Q2 24 | $53.0M | $-39.0M | ||
| Q1 24 | — | $-62.5M | ||
| Q4 23 | — | $-14.1M |
自由现金流
BUR
LAB
| Q4 25 | $-29.3M | — | ||
| Q3 25 | $-20.1M | $-23.1M | ||
| Q2 25 | $-84.3M | $-22.6M | ||
| Q1 25 | $155.1M | $-35.3M | ||
| Q3 24 | $-97.4M | $-30.1M | ||
| Q2 24 | $52.9M | $-41.0M | ||
| Q1 24 | — | $-63.3M | ||
| Q4 23 | — | $-14.1M |
自由现金流率
BUR
LAB
| Q4 25 | -87.7% | — | ||
| Q3 25 | -28.8% | -118.1% | ||
| Q2 25 | -44.1% | -103.6% | ||
| Q1 25 | 130.5% | -86.6% | ||
| Q3 24 | -61.0% | -136.4% | ||
| Q2 24 | 119.5% | -182.2% | ||
| Q1 24 | — | -138.9% | ||
| Q4 23 | — | -50.2% |
资本支出强度
BUR
LAB
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.1% | 4.5% | ||
| Q2 25 | 0.1% | 8.7% | ||
| Q1 25 | 0.0% | 12.4% | ||
| Q3 24 | 0.0% | 10.2% | ||
| Q2 24 | 0.1% | 8.6% | ||
| Q1 24 | — | 1.7% | ||
| Q4 23 | — | 0.3% |
现金转化率
BUR
LAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.95× | — | ||
| Q1 25 | 5.02× | — | ||
| Q3 24 | -1.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BUR
| Principal Finance Segment | $29.1M | 87% |
| Other | $3.5M | 10% |
| Management Fee Income | $878.0K | 3% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |